Clinical trials sponsored by Relay Therapeutics, Inc.

Phase breakdown

Conditions studied

Recruiting trials led by Relay Therapeutics, Inc.

• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
  NCT07584226 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 231 locations

Common questions

How many trials is Relay Therapeutics, Inc. recruiting for?

Relay Therapeutics, Inc. is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.